Physiomics plc
("Physiomics" or "the Company")
Recent Price Movements
The directors of Physiomics confirm that they know of no reason for the recent movements in the Company's share price.
The directors can also confirm that, as previously announced on 31 August 2010, they are actively progressing discussions with Jubliant Biosys Limited ("Jubilant"), with regards to a collaboration and potential joint services alliance. It is now anticipated that any final agreement will be completed by the end of 2010.
A further announcement will be made in due course, if an agreement is executed.
Enquiries:
Physiomics plc
Dr Christophe Chassagnole, COO
+44 (0)1865 784980
WH Ireland Limited
Katy Mitchell
+44 (0) 161 832 2174
About Physiomics plc
Physiomics plc (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates1 show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million.
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating most important molecular events taking place during the human cell cycle and apoptosis processes. Physiomics developed SystemCell® technology, a multi-cellular environment software, which enables the simulation of population of "virtual cells".
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com
SystemCell® is a registered trademark of Physiomics plc
1Tufts Centre Impact Report 2002